AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04380207
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT04380207
Drug: QPX2014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antibiotic
Trial: NCT00029731
Drug: Arginine hydrochloride
RxNorm normalized name: Arginine Hydrochloride
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00678561
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment once daily for 28 days
Trial: NCT00678561
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment twice daily for 28 days
Trial: NCT00678561
Drug: Placebo Vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment once daily for 28 days
Trial: NCT00678561
Drug: Placebo Vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment twice daily for 28 days
Trial: NCT04464642
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate 25 mg subcutaneous is given in group A
Trial: NCT03273036
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no injected agent
Trial: NCT01236404
Drug: Multiple (Four Weekly) Subcutaneous Injections (Part B) of PB1023 or Placebo (0.9% NaCl)
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly injections for up to four weeks
Trial: NCT01941953
Drug: Metformin and Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: metformin 850mg PO BID plus 5FU 425mg/m2 + leucovorin 50mg IV weekly
Trial: NCT04329494
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04547361
Drug: E2511
RxNorm normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: E2511 tablets.
Trial: NCT04547361
Drug: E2511 Matched Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets matching E2511 tablets.
Trial: NCT03704610
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An initial period with 2 injections with placebo allowing the determination of the primary criteria Then an extension with infliximab with 5 supplementary perfusions
Trial: NCT01328002
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo tablets daily
Trial: NCT02869971
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combodart (dutasteride 0.5 mg/tamsulosin 0.4 mg)
Trial: NCT01306617
Drug: ABT-450
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets
Trial: NCT01306617
Drug: ABT-333
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets
Trial: NCT01494311
Drug: Placebo Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo patch was placed on each patient's wrist in the region of the maximum radial artery pulsation. After 20 minutes, the patch was removed.
Trial: NCT01494311
Drug: Subcutaneous injection of 0.5 ml Lidocain 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After removing the patch, a blinded investigator injected 0.5 ml of 1% lidocaine solution. Three minutes after injection, an attempt was made to cannulate the radial artery with a 20-gauge catheter.
Trial: NCT01494311
Drug: Subcutaneous injection of saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After removing the patch, a blinded investigator injected 0.5 ml saline solution. Three minutes after injection, an attempt was made to cannulate the radial artery with a 20-gauge catheter.
Trial: NCT03049163
Drug: vitrectomy under topical anesthesia [Proparacaine HCL (Alcaine®)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: to observe the anesthesia effect of topical anesthesia of 27-gauge vitrectomy for vitreous floaters
Trial: NCT00349492
Drug: IP
RxNorm normalized name: GIP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: irinotecan+cisplatin
Trial: NCT02047604
Drug: SAN-300 0.5 mg/kg QW
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02047604
Drug: SAN-300 1.0 mg/kg QW
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02047604
Drug: SAN-300 2.0 mg/kg QOW
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02047604
Drug: SAN-300 4.0 mg/kg QOW
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02047604
Drug: SAN-300 4.0 mg/kg QW
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02047604
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02381080
Drug: Erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin 500 mg tablet will be taken orally TID (Part1 Cycle 1: on Days 5-10 and morning dose on Day 11; Part2 Cycle 1: on Days 5-17 and morning dose on Day 18).
Trial: NCT01976416
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00216294
Drug: RG1068 (Synthetic Human Secretin)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03135522
Drug: Zinc Acetate 50 Mg Oral Capsule
RxNorm normalized name: zinc acetate 50 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Day 0 (randomization) to day 3 Zinc acetate 50 mg per day (one capsule)~* Day 4 to day 7 If well tolerated: Zinc acetate 100 mg per day (two capsules)~* Day 8 to V5 (6 weeks) If well tolerated: Zinc acetate 150 mg per day (three capsules)
Trial: NCT03135522
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Day 0 (randomization) to day 3 Placebo (one capsule per day)~* Day 4 to day 7 If well tolerated: placebo (two capsules per day)~* Day 8 to V5 (6 weeks) If well tolerated: placebo (three capsules per day)
Trial: NCT03281811
Drug: Aminolevulinic Acid Hydrochloride
RxNorm normalized name: Aminolevulinic Acid Hydrochloride
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given topically
Trial: NCT03281811
Drug: Photodynamic Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undergo PDT
Trial: NCT03436472
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline infusion
Trial: NCT00885872
Drug: Rosuvastatin (Crestor)
RxNorm normalized name: rosuvastatin Oral Tablet [Crestor]
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: at visit 2 each eligible subject will be allocated to rosuvastatin. study medication wil be taken orally with water once daily, as directed by the study physician. subjects who meet the criteria at visit 3, dosage of rosuvastatin will be titrated.
Trial: NCT03779841
Drug: AGN-151607
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injections were made into each 1 of 5 fat pads. The total injection volume into each fat pad was 1 mL. One-time treatment.
Trial: NCT03779841
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injections of placebo were made into each 1 of 5 fat pads. The total injection volume into each fat pad was 1 mL. One-time treatment.
Trial: NCT00672477
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04466514
Drug: ASTX029
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form: tablet; Route of Administration: oral
Trial: NCT01176591
Drug: Placebo session 1, Placebo session 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, one per session, oral administration
Trial: NCT00515333
Drug: TRx0014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hard capsule; 60 milligrams; t.i.d.
Trial: NCT00515333
Drug: TRx0014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hard capsule; 30 milligrams; t.i.d.
Trial: NCT00515333
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hard capsule; 0 milligrams; t.i.d.
Trial: NCT00515333
Drug: TRx0014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hard capsule, 100 milligrams, t.i.d.
Trial: NCT00453765
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01221441
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intraarticular injection of normal saline as a placebo control
Trial: NCT01322204
Drug: Codeine
RxNorm normalized name: Codeine
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One single oral dose of 1 mg/kg of codeine
Trial: NCT04147013
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive celecoxib 200 mg PO BID for 7 days post endoscopic sinus surgery, starting on the evening of the day of surgery.
Trial: NCT04147013
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive placebo PO BID for 7 days post endoscopic sinus surgery, starting on the evening of the day of surgery.
Trial: NCT00466193
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo sublingual tablet taken as needed following a middle-of-the-night awakening over the 28-night study period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
Trial: NCT02944578
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants randomized to the placebo arm will insert four 500 mg (2000 mg total) of the placebo (gelatin) capsules once a week (excluding days when they are on their menses). Participants will insert the capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology, colposcopies and biopsies will be performed at the Baseline, Week 4, 8, 12 and 16 visits to collect samples to analyze for the study outcomes.
Trial: NCT01257204
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, oral, 0 mg, once daily, for 24 weeks
Trial: NCT01621399
Drug: Product 55394
RxNorm normalized name: Pyelocalyceal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Product 55394 vaginal gel in a prefilled applicator.
Trial: NCT01621399
Drug: Placebo Vehicle (non-treatment)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The vehicle vaginal gel in an applicator (placebo).
Trial: NCT04622254
Drug: NT 201
RxNorm normalized name: Fluarix Quadrivalent 2013-2014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Trial: NCT04622254
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection prepared by reconstitution of powder with percent (%) Sodium Chloride (NaCl).
Trial: NCT02744846
Drug: Antibiotics exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02575781
Drug: SAR428926
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:concentrate for solution for infusion Route of administration: intravenous
Trial: NCT00004357
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01040429
Drug: Lactose capsula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 1-56 (week 1-8): 1 capsula x 2/day for patients \< 35 kg; 2 capsula x 2/day for patients \> 35 kg.~Day 57-63 (week 9): 1 capsula x 1/day for patients \< 35 kg; 1 capsula x 2/day for patients \> 35 kg
Trial: NCT02180425
Drug: Tretinoin or Adapalene
RxNorm normalized name: adapalene Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will apply a pea sized amount of topical retinoid cream once daily at night for 30 days. Subjects will return for a follow-up visit.
Trial: NCT00679991
Drug: PRT-201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied topically to AVF during surgery
Trial: NCT00679991
Drug: PRT-201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation study. Drug/placebo administered at the time of fistula creation
Trial: NCT00323739
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAD001 10 mg by mouth daily
Trial: NCT00456092
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules for oral administration
Trial: NCT00068055
Drug: Omr-lgG-am
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omr-IgG-am™ 5% is provided in 100 ml bottles (5.0 grams) as a sterile solution containing 5% protein, 10% maltose and water for injection. This product is licensed in Israel, but not in the US.
Trial: NCT00068055
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline.
Trial: NCT02472665
Drug: plasma-derived FVIII/VWF concentrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 single dose of 80 IU/kg VWF:RCo of Fanhdi will be administered
Trial: NCT01312402
Drug: Placebo in 5 mL dispenser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ophthalmic solution in 5 mL dispenser; 1 drop three times a day on days 2,3 and 4
Trial: NCT00009230
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02660736
Drug: Placebo Liquid Auto-injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid albiglutide matching placebo is provided as a fixed-dose, disposable autoinjector containing placebo liquid. The auto-injector delivers the placebo in an injection volume of 1.0 mL for the 50 mg placebo dose.
Trial: NCT02660736
Drug: Placebo Lyophilized DCC Pen injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is supplied as prefilled DCC Pen Injector. Each DCC contains matching placebo. When the injector pen product is reconstituted a neutral, isotonic placebo solution is produced. The pen delivers the placebo in an injection volume of 0.5 mL.
Trial: NCT04412902
Drug: adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy and/or radiotherapy
Trial: NCT01540227
Drug: Regular Treatment for Syphilis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Benzathine Penicillin G (Bicillin)~Dose: 2.4 million units~Mode of Administration: intramuscular injection~Duration of Treatment: one dose~Health Canada approved indication: Yes
Trial: NCT00563797
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill
Trial: NCT03586869
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Trial: NCT03586869
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Trial: NCT03586869
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione
Trial: NCT03586869
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
Trial: NCT01198184
Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00812929
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The current study will include a placebo arm to allow for a valid evaluation of adverse events attributable to GSK2190915 versus those independent of GSK2190915.
Trial: NCT00812929
Drug: GSK2190915
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study will assess FEV1 at various intervals following exercise challenge in subjects who have been administered a single dose of 10 mg, 50 mg, 100 mg, or 200 mg GSK2190915, compared to a placebo control.
Trial: NCT01070927
Drug: RO4929097
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80mg po daily, 3 days on 4 days off schedule
Trial: NCT01070927
Drug: RO4929097
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recommended phaseII dose, orally once daily, 3 days on 4 days off schedule
Trial: NCT01646671
Drug: LCZ696
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCZ696 200 mg tablet once daily
Trial: NCT01646671
Drug: LCZ696
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily
Trial: NCT01646671
Drug: LCZ696
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily plus other HTN medications
Trial: NCT02359292
Drug: CHF 5993 HS 200/6/25 pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02359292
Drug: CHF 5993 MS 100/6/25 pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02359292
Drug: CHF 5993 HS 200/6/25 pMDI + Charcoal Block
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02359292
Drug: CHF 5993 MS 100/6/25 pMDI + Charcoal Block
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02359292
Drug: Placebo pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02443298
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for risankizumab
Trial: NCT05846009
Drug: SAR442501
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT05846009
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT01116089
Drug: Bramitob® administered by PARI LC® PLUS nebulizer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (tobramycin 300mg /4mL) solution administered by inhalation twice daily for 28 days
Trial: NCT01116089
Drug: Bramitob® administered by PARI eFlow® rapid electronic nebulizer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (tobramycin 300mg /4mL) solution administered by inhalation twice daily for 28 days
Trial: NCT00237952
Drug: EDTA chelating agents
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01991834
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of saline sterile solution
Trial: NCT00647855
Drug: Levothyroxine Sodium Tablets 300 μg
RxNorm normalized name: levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2x300mcg, single dose fasting
Trial: NCT00647855
Drug: Synthroid® Tablets 300 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2x300mcg, single dose fasting
Trial: NCT03610490
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04096560
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-994 placebo-matching tablets.
Trial: NCT03204942
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Similar to the previous groups, but without applying any type of Radio-frequency but just injecting steroids and local anesthetics as previously described
Trial: NCT00103792
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 mg/kg/d, combined with steroids, for remission induction, followed by standard azathioprine maintenance therapy
Trial: NCT02791334
Drug: LY3300054
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT02791334
Drug: LY3321367
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT03858075
Drug: BLU-782
RxNorm normalized name: Blu-Kote
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsules
Trial: NCT03858075
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsules
Trial: NCT03858075
Drug: BLU-782 taken with food
RxNorm normalized name: Blu-Kote
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsules
Trial: NCT02651623
Drug: Drug - Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered for 14 days
Trial: NCT01260987
Drug: Conventional photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy using methyl-aminolevulinate and red light (37 J/cm2)
Trial: NCT01260987
Drug: Fractional CO2 laser assisted PDT
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pretreatment with fractional CO2 laser before methyl-aminolevulinate PDT
Trial: NCT04083872
Drug: Reference drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D744 Cap. 1 Cap., single oral administration under fasting condition
Trial: NCT04083872
Drug: Test drug
RxNorm normalized name: URINE TEST DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CKD-385 64 mg formulation I Tab. 1 Tab., single oral administration under fasting condition
Trial: NCT01000051
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once a day, orally for 8 weeks.
Trial: NCT00726115
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03732248
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inert drug